S1P lyase inhibition protects against sepsis by promoting disease tolerance via the S1P/S1PR3 axis.

ABSTRACT:

Background

One-third of all deaths in hospitals are caused by sepsis. Despite its demonstrated prevalence and high case fatality rate, antibiotics remain the only target-oriented treatment option currently available. Starting from results showing that low-dose anthracyclines protect against sepsis in mice, we sought to find new causative treatment options to improve sepsis outcomes.

Methods

Sepsis was induced in mice, and different treatment options were evaluated regarding cytokine and biomarker expression, lung epithelial cell permeability, autophagy induction, and survival benefit. Results were validated in cell culture experiments and correlated with patient samples.

Findings

Effective low-dose epirubicin treatment resulted in substantial downregulation of the sph

SUBMITTER: Weigel C 

PROVIDER: S-EPMC7381498 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature